@article{black_mmr_2003,
	title = {{MMR} vaccine and idiopathic thrombocytopaenic purpura},
	volume = {55},
	issn = {0306-5251},
	abstract = {AIMS: To estimate the relationship between idiopathic thrombocytopaenic purpura (ITP) and the measles, mumps and rubella (MMR) vaccination in children; calculating the relative risk estimate for ITP with in 6 weeks after MMR vaccination and the attributable risk of ITP within 6 weeks after MMR vaccination.
METHODS: Using the General Practice Research Database we identified children with a first-time diagnosis of ITP from a base population of children aged less than 6 years between January 1988 and December 1999. After describing the characteristics of all the children identified with ITP, we focused on cases aged 13-24 months to perform a population-based, case-control analysis to estimate the relative risk of developing ITP within 6 weeks after MMR vaccination. We also calculated the risk of ITP attributable to the MMR vaccination.
RESULTS: Sixty-three children with a first time diagnosis of ITP were identified; 23 cases were between 13 and 24 months old. The relative risk estimate for ITP within 6 weeks after MMR vaccination, compared to the combined group of unvaccinated children and children vaccinated with MMR more than 26 weeks previously was 6.3 (95\% CI 1.3-30.1). The attributable risk of developing ITP within 6 weeks after MMR vaccination was estimated to be 1 in 25,000 vaccinations (95\% confidence interval 21,300, 89,400).
CONCLUSION: This study confirms the increased risk of ITP within 6 weeks after MMR vaccination. However, the attributable risk of ITP within 6 weeks after MMR vaccination is low.},
	language = {eng},
	number = {1},
	journal = {British Journal of Clinical Pharmacology},
	author = {Black, Corri and Kaye, James A. and Jick, Hershel},
	month = jan,
	year = {2003},
	pmid = {12534647},
	pmcid = {PMC1884189},
	keywords = {Case-Control Studies, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Measles-Mumps-Rubella Vaccine, Purpura, Thrombocytopenic, Idiopathic, Risk Factors},
	pages = {107--111}
}

{"_id":"89ETKmunQtYyFaDmC","bibbaseid":"black-kaye-jick-mmrvaccineandidiopathicthrombocytopaenicpurpura-2003","downloads":0,"creationDate":"2017-08-15T09:38:10.625Z","title":"MMR vaccine and idiopathic thrombocytopaenic purpura","author_short":["Black, C.","Kaye, J. A.","Jick, H."],"year":2003,"bibtype":"article","biburl":"http://bibbase.org/zotero/veegee78","bibdata":{"bibtype":"article","type":"article","title":"MMR vaccine and idiopathic thrombocytopaenic purpura","volume":"55","issn":"0306-5251","abstract":"AIMS: To estimate the relationship between idiopathic thrombocytopaenic purpura (ITP) and the measles, mumps and rubella (MMR) vaccination in children; calculating the relative risk estimate for ITP with in 6 weeks after MMR vaccination and the attributable risk of ITP within 6 weeks after MMR vaccination. METHODS: Using the General Practice Research Database we identified children with a first-time diagnosis of ITP from a base population of children aged less than 6 years between January 1988 and December 1999. After describing the characteristics of all the children identified with ITP, we focused on cases aged 13-24 months to perform a population-based, case-control analysis to estimate the relative risk of developing ITP within 6 weeks after MMR vaccination. We also calculated the risk of ITP attributable to the MMR vaccination. RESULTS: Sixty-three children with a first time diagnosis of ITP were identified; 23 cases were between 13 and 24 months old. The relative risk estimate for ITP within 6 weeks after MMR vaccination, compared to the combined group of unvaccinated children and children vaccinated with MMR more than 26 weeks previously was 6.3 (95% CI 1.3-30.1). The attributable risk of developing ITP within 6 weeks after MMR vaccination was estimated to be 1 in 25,000 vaccinations (95% confidence interval 21,300, 89,400). CONCLUSION: This study confirms the increased risk of ITP within 6 weeks after MMR vaccination. However, the attributable risk of ITP within 6 weeks after MMR vaccination is low.","language":"eng","number":"1","journal":"British Journal of Clinical Pharmacology","author":[{"propositions":[],"lastnames":["Black"],"firstnames":["Corri"],"suffixes":[]},{"propositions":[],"lastnames":["Kaye"],"firstnames":["James","A."],"suffixes":[]},{"propositions":[],"lastnames":["Jick"],"firstnames":["Hershel"],"suffixes":[]}],"month":"January","year":"2003","pmid":"12534647","pmcid":"PMC1884189","keywords":"Case-Control Studies, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Measles-Mumps-Rubella Vaccine, Purpura, Thrombocytopenic, Idiopathic, Risk Factors","pages":"107--111","bibtex":"@article{black_mmr_2003,\n\ttitle = {{MMR} vaccine and idiopathic thrombocytopaenic purpura},\n\tvolume = {55},\n\tissn = {0306-5251},\n\tabstract = {AIMS: To estimate the relationship between idiopathic thrombocytopaenic purpura (ITP) and the measles, mumps and rubella (MMR) vaccination in children; calculating the relative risk estimate for ITP with in 6 weeks after MMR vaccination and the attributable risk of ITP within 6 weeks after MMR vaccination.\nMETHODS: Using the General Practice Research Database we identified children with a first-time diagnosis of ITP from a base population of children aged less than 6 years between January 1988 and December 1999. After describing the characteristics of all the children identified with ITP, we focused on cases aged 13-24 months to perform a population-based, case-control analysis to estimate the relative risk of developing ITP within 6 weeks after MMR vaccination. We also calculated the risk of ITP attributable to the MMR vaccination.\nRESULTS: Sixty-three children with a first time diagnosis of ITP were identified; 23 cases were between 13 and 24 months old. The relative risk estimate for ITP within 6 weeks after MMR vaccination, compared to the combined group of unvaccinated children and children vaccinated with MMR more than 26 weeks previously was 6.3 (95\\% CI 1.3-30.1). The attributable risk of developing ITP within 6 weeks after MMR vaccination was estimated to be 1 in 25,000 vaccinations (95\\% confidence interval 21,300, 89,400).\nCONCLUSION: This study confirms the increased risk of ITP within 6 weeks after MMR vaccination. However, the attributable risk of ITP within 6 weeks after MMR vaccination is low.},\n\tlanguage = {eng},\n\tnumber = {1},\n\tjournal = {British Journal of Clinical Pharmacology},\n\tauthor = {Black, Corri and Kaye, James A. and Jick, Hershel},\n\tmonth = jan,\n\tyear = {2003},\n\tpmid = {12534647},\n\tpmcid = {PMC1884189},\n\tkeywords = {Case-Control Studies, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Measles-Mumps-Rubella Vaccine, Purpura, Thrombocytopenic, Idiopathic, Risk Factors},\n\tpages = {107--111}\n}\n\n","author_short":["Black, C.","Kaye, J. A.","Jick, H."],"key":"black_mmr_2003","id":"black_mmr_2003","bibbaseid":"black-kaye-jick-mmrvaccineandidiopathicthrombocytopaenicpurpura-2003","role":"author","urls":{},"keyword":["Case-Control Studies","Child","Child","Preschool","Female","Humans","Infant","Infant","Newborn","Male","Measles-Mumps-Rubella Vaccine","Purpura","Thrombocytopenic","Idiopathic","Risk Factors"],"downloads":0},"search_terms":["mmr","vaccine","idiopathic","thrombocytopaenic","purpura","black","kaye","jick"],"keywords":["case-control studies","child","child","preschool","female","humans","infant","infant","newborn","male","measles-mumps-rubella vaccine","purpura","thrombocytopenic","idiopathic","risk factors"],"authorIDs":[],"dataSources":["FmCWXwJibZiWNzpdc"]}